<div id="readability-page-1"><p>ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.65) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.65), Zacks reports.</p><div><p><span></span><span>Get <strong>ArriVent BioPharma</strong> alerts:</span></p></div><h2>ArriVent BioPharma Stock Down 0.4 %</h2><p>AVBP traded down $0.09 on Thursday, hitting $23.86. 110,115 shares of the company traded hands, compared to its average volume of 122,485. ArriVent BioPharma has a 12-month low of $14.35 and a 12-month high of $25.95. The company has a 50 day moving average of $19.57 and a 200-day moving average of $19.16. </p><h2>Analyst Upgrades and Downgrades</h2><p>AVBP has been the topic of several analyst reports. Oppenheimer reaffirmed an &#34;outperform&#34; rating and issued a $35.00 target price on shares of ArriVent BioPharma in a report on Thursday. HC Wainwright reissued a &#34;buy&#34; rating and issued a $25.00 target price on shares of ArriVent BioPharma in a report on Thursday, June 6th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of &#34;Buy&#34; and an average price target of $30.40.</p><p><b>Check Out Our Latest Stock Report on ArriVent BioPharma</b></p><h2>ArriVent BioPharma Company Profile</h2> (Get Free Report)<p>ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than ArriVent BioPharma</li><li>How Investors Can Find the Best Cheap Dividend Stocks</li><li>Michael Burry's Alibaba Bet and the Broader Market Implications</li><li>How to Use the MarketBeat Excel Dividend Calculator</li><li>Jeff Brown's Exegesis AI Stock Picks</li><li>Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time</li><li>Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><p>→ Your iPhone windfall? <span><span>(From InvestorPlace)</span> <span>(Ad)</span></span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTc4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTc4"/></p><h2>Should you invest $1,000 in ArriVent BioPharma right now?</h2><p>Before you consider ArriVent BioPharma, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ArriVent BioPharma wasn't on the list.</p><p>While ArriVent BioPharma currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p> </div>

.IXIC

.NDXTMC

AVBP

<p>ArriVent BioPharma (NASDAQ:AVBP) announced its quarterly earnings results, reporting an EPS that met analysts' expectations. Despite this, the stock fell by 0.4%, trading at $0.86. The company's target price has been reaffirmed by analysts, with Oppenheimer and HC Wainwright both issuing buy ratings. The stock currently holds a consensus rating of "Buy" with an average target of $1.40. ArriVent focuses on developing targeted cancer therapies, particularly for non-small cell lung cancer.</p>